偏头痛市场:KOL的洞察
市场调查报告书
商品编码
1428593

偏头痛市场:KOL的洞察

Migraine - KOL Insight

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告研究了全球偏头痛市场,并提供了市场概况,以及上市的治疗方法、管道趋势和未来前景。

目录

摘要整理

现在及未来的治疗流程

调查目的

市售治疗方法

  • 肉毒桿菌毒素(肉毒桿菌毒素A; 艾伯维(AbbVie)
  • Aimovig(elenumab/elenumab-aooe,安进/诺华)
  • 阿乔比(fremanezumab/fremanezumab-VFRM; Teva)
  • Emgality(galcanezumab/galcanezumab-gnlm; 礼来)
  • Leyvaux/Leyvaux (Las Miditan, Lilly)
  • 乌布雷尔维(Ubrozepanto; 艾伯维(AbbVie)
  • Nurtec ODT/维杜拉 辉瑞)
  • Qulipta/Aquipta(atogepant; 艾伯维(AbbVie)
  • Vyepti(eptinezumab; 灵北)
  • Zabuzupret(Zabegepanto; 辉瑞)

初期阶段的开发计划

口服凝胶和皮下抗CGRP单克隆抗体的当前动力学

偏头痛治疗的未来展望

附录

简介目录

Why do many KOLs prefer Teva's Ajovy or Lilly's Emgality over Amgen/Novartis' Aimovig for the preventive management of migraine? Over the next five years, neurologists anticipate subcutaneous anti-CGRP mAbs will challenge Botox as the first-line treatment for migraine prevention, but that use of Lundbeck's Vyepti will remain limited - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

  • How do KOLs assess the potential impact of Xeomin, Dysport and prabotulinumtoxinA on the use of AbbVie's well-established Botox?
  • Why are experts impressed by AbbVie's Botox+ Qulipta/Aquipta combination trial?
  • How do KOLs prescribe Pfizer's Nurtec ODT/Vydura, and what other studies do experts recommend?
  • What underpins neurologists' opinion that AbbVie's Qulipta/Aquipta is preferable to Pfizer's Nurtec ODT in the preventive management of migraine?
  • Why do neurologists say that despite being an effective treatment, Lilly's lasmiditan is currently reserved for later-line therapy?
  • Why are KOLs not particularly impressed by the clinical data for Pfizer's Zavzpret?

Key brands covered in this report:

  • Botox
  • Aimovig
  • Ajovy
  • Emgality
  • Reyvow/Rayvow
  • Ubrelvy
  • Nurtec ODT/Vydura
  • Qulipta/Aquipta
  • Vyepti
  • Zavzpret

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (3)

Marketed therapies (137)

  • Botox (onabotulinum toxin A; AbbVie) (18)
    • Key insights summary (18)
  • Aimovig (erenumab/erenumab-aooe; Amgen/Novartis) (10)
    • Key insights summary (10)
  • Ajovy (fremanezumab/fremanezumab-vfrm; Teva) (10)
    • Key insights summary (10)
  • Emgality (galcanezumab/galcanezumab-gnlm; Lilly) (10)
    • Key insights summary (10)
  • Reyvow/Rayvow (lasmiditan; Lilly) (14)
    • Key insights summary (14)
  • Ubrelvy (ubrogepant; AbbVie) (9)
    • Key insights summary (9)
  • Nurtec ODT/Vydura (rimegepant; Pfizer) (16)
    • Key insights summary (16)
  • Qulipta/Aquipta (atogepant; AbbVie) (16)
    • Key insights summary (16)
  • Vyepti (eptinezumab; Lundbeck) (21)
    • Key insights summary (21)
  • Zavzpret (zavegepant; Pfizer) (13)
    • Key insights summary (13)

Early-stage development programmes (22)

  • Key insights summary (22)
    • KOLs are pleased with the Phase II HOPE trial and are enthusiastic about the potential of PACAP therapy in migraine treatment (20)

Current dynamics of oral gepants and subcutaneous anti-CGRP mAbs (12)

  • Key insights summary (12)
    • Better tolerability profile of oral gepants makes them the preferred option over triptans: some KOLs favour subcutaneous mAbs over oral gepants due to adherence issues (10)

Future Outlook for the Migraine Therapies (10)

  • Key insights summary (10)
    • Neurologists foresee triptans to remain a standard choice for acute migraine, with gepants being the second line of treatment (8)

Appendix (4)

  • KOL details (4)